MEMohammad Elsayed

Mohammad Elsayed

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mohammad Elsayed has a total of 74 co-authors. Here are the top co-authors by number of shared publications:

  • Nima Kokabi

    Division of Interventional Radiology and Image-Guided Medicine, Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, USA

    4 shared publications
  • Abdel-Rahman Nabawy Zekri

    Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo 11976, Egypt

    2 shared publications
  • Adie Friedman

    Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA

    2 shared publications
  • Ahmed Ihab Abdelaziz

    School of Medicine, Newgiza University (NGU), Giza 12577, Egypt

    2 shared publications
  • Ayman Salah

    Department of Surgery, Cairo University, Cairo 11562, Egypt

    2 shared publications
  • Bill S. Majdalany

    Division of Interventional Radiology and Image-Guided Medicine, Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, USA

    2 shared publications

Latest Publications

  • Three-Dimensional Margin as a Predictor of Local Tumor Progression after Microwave Ablation: Intraprocedural versus 4–8-Week Postablation Assessment

    by Mahdi Zirakchian Zadeh, Vlasios S. Sotirchos, Assen Kirov, Daniel Lafontaine, Mithat Gönen, Randy Yeh, Henry Kunin, Elena N. Petre, Yuliya Kitsel, Mohammad Elsayed, et al.


  • Open Access

    Antitumor Activity of Metformin Combined with Locoregional Therapy for Liver Cancer: Evidence and Future Directions

    by Eshani J. Choksi, Mohammad Elsayed, Nima Kokabi

    This article aimed to examine the effect of metformin use on improving outcomes after liver-directed therapy in patients with HCC and identify future directions with the adjuvant use of and potential therapeutic agents that operate on similar mechanistic pathways. Databases were queried to identify pertinent articles on metformin’s use as an anti-cancer agent in HCC. Eleven studies were included, with five pre-clinical and six clinical studies. The mean overall survival (OS) and progression-free survival were both higher in the locoregional therapy (LRT) + metformin-treated groups. The outcome variables, including local tumor recurrence rate, reduction in HCC tumor growth and size, tumor growth, proliferation, migration and invasion of HCC cells, HCC cell apoptosis, DNA damage, and cell cycle arrest, showed favorable outcomes in the LRT + metformin-treated groups compared with LRT alone. This systemic review provides a strong signal that metformin use can improve the tumor response after locoregional therapy. Well-controlled prospective trials will be needed to elucidate the potential antitumor effects of metformin and other mTOR inhibitors.


  • Interventional Oncology: 2043 and Beyond

    by Mohammad Elsayed, Stephen B. Solomon

    Interventional oncology is a subspecialty of interventional radiology focused on treating patients with cancer using minimally invasive, image-guided procedures. The role of interventional oncology has become so integral for supporting patients with cancer that many consider it the fourth pillar of oncology-a recent addition to the traditional pillars of medical oncology, surgery, and radiation oncology. As highlighted herein, the authors predict opportunities for growth in precision oncology, immunotherapy, advanced imaging, and novel interventions, facilitated by emergent technologies like artificial intelligence, gene editing, molecular imaging, and robotics. Beyond these technological breakthroughs, however, the defining characteristic of interventional oncology in 2043 will be a well-developed clinical and research infrastructure that enables greater integration of interventional oncology procedures into standard practice.


  • Use of Metformin and Survival in Patients with Hepatocellular Carcinoma (HCC) Undergoing Liver Directed Therapy: Analysis of a Nationwide Cancer Registry

    by Kumar Mukherjee, Mohammad Elsayed, Eshani Choksi, Mohammed F. Loya, Richard Duszak, Mehmet Akce, Bill S. Majdalany, Zachary L. Bercu, Mircea Cristescu, Nima Kokabi

    Background Examine the association of metformin use and overall survival (OS) in patients with HCC undergoing image-guided liver-directed therapy (LDT): ablation, transarterial chemoembolization (TACE), or Yttrium-90 radioembolization (Y90 RE). Methods Using National Cancer Institute Surveillance, Epidemiology, and End Results registry and Medicare claims databases between 2007 and 2016, we identified patients ≥ 66 years who underwent LDT within 30 days of HCC diagnosis. Patients with liver transplant, surgical resection, and other malignancies were excluded. Metformin use was identified by at least two prescription claims within 6 months before LDT. OS was measured by time between first LDT and death or last Medicare observation. Comparisons were performed between both all and diabetic patients on and not on metformin. Results Of 2746 Medicare beneficiaries with HCC undergoing LDT, 1315 (47.9%) had diabetes or diabetes-related complications. Among all and diabetic patients, 433(15.8%) and 402 (30.6%) were on metformin respectively. Median OS was greater for patients on metformin (19.6 months, 95% CI 17.1–23.0) vs those not (16.0 months, 15.0–16.9; p = 0.0238). Patients on metformin had lower risk of death undergoing ablation (HR 0.70; 0.51–0.95; p = 0.0239) and TACE (HR 0.76, 0.66–0.87; p = 0.0001), but not Y90 RE (HR1.22, 0.89–1.69; p = 0.2231). Among diabetics, OS was greater for those on metformin vs those not (HR 0.77, 0.68–0.88; p < 0.0001). Diabetic patients on metformin had longer OS undergoing TACE (HR 0.71, 0.61–0.83; p < 0.0001), but not ablation (HR 0.74, 0.52–1.04; p = 0.0886) or Y90 RE (HR 1.26, 0.87–1.85; p = 0.2217). Conclusion Metformin use is associated with improved survival in HCC patients undergoing TACE and ablation.


  • Open Access

    Extrinsic arterial compression and lower extremity ischemia after iliac vein stent placement: case report, review of literature

    by Mohammad Elsayed, Debkumar Sarkar, Ken Zhao, Yolanda Bryce, Adie Friedman

    Background: Lower extremity ischemia due to extrinsic arterial compression by venous stent placement is a rare but increasingly recognized occurrence. Given the rise of complex venous interventions, awareness of this entity is becoming increasingly important to avoid serious complications. Case Presentation: A 26-year-old with progressively enlarging pelvic sarcoma despite chemoradiation developed recurrent symptomatic right lower extremity deep venous thrombosis due to worsening mass effect on a previously placed right common iliac vein stent. This was treated with thrombectomy and stent revision, with extension of the right common iliac vein stent to the external iliac vein. During the immediate post-procedure period the patient developed symptoms of acute right lower extremity arterial ischemia including diminished pulses, pain, and motorsensory loss. Imaging confirmed extrinsic compression of the external iliac artery by the newly placed adjacent venous stent. The patient underwent stenting of the compressed artery with complete resolution of ischemic symptoms. Conclusions: Awareness and early recognition of arterial ischemia following venous stent placement is important to prevent serious complication. Potential risk factors include patients with active pelvis malignancy, prior radiation, or scarring from surgery or other inflammatory processes. In cases of threatened limb, prompt treatment with arterial stenting is recommended. Further study is warranted to optimize detection and management of this complication.


  • Creation of a Ureteroileal Conduit Neoanastomosis Using a Radiofrequency Guide Wire

    by Mohammad Elsayed, Liwei Jiang, Fourat Ridouani, Ernesto Santos

  • Open Access

    Extrinsic Arterial Compression and Lower Extremity Ischemia After Iliac Vein Stent Placement: Case Report and Review of Literature

    by Mohammad Elsayed, Debkumar Sarkar, Ken Zhao, Yolanda Bryce, Adie Friedman

    Background Lower extremity ischemia due to extrinsic arterial compression by venous stent placement is a rare but increasingly recognized occurrence. Given the rise of complex venous interventions, awareness of this entity is becoming increasingly important to avoid serious complications. Case Presentation A 26-year-old with progressively enlarging pelvic sarcoma despite chemoradiation developed recurrent symptomatic right lower extremity deep venous thrombosis due to worsening mass effect on a previously placed right common iliac vein stent. This was treated with thrombectomy and stent revision, with extension of the right common iliac vein stent to the external iliac vein. During the immediate post-procedure period the patient developed symptoms of acute right lower extremity arterial ischemia including diminished pulses, pain, and motorsensory loss. Imaging confirmed extrinsic compression of the external iliac artery by the newly placed adjacent venous stent. The patient underwent stenting of the compressed artery with complete resolution of ischemic symptoms. Conclusions Awareness and early recognition of arterial ischemia following venous stent placement is important to prevent serious complication. Potential risk factors include patients with active pelvis malignancy, prior radiation, or scarring from surgery or other inflammatory processes. In cases of threatened limb, prompt treatment with arterial stenting is recommended. Further study is warranted to optimize detection and management of this complication.

  • Open Access

    Percutaneous transhepatic cholangioscopy-guided lithotripsy and retrieval of vascular coils eroded into the biliary tree

    by Mohammad Elsayed, Nariman Nezami, Nima Kokabi, Geoffrey M. Scriver, Moataz M. Behairy, Bill S. Majdalany


  • Improved Tumor Response in Patients on Metformin Undergoing Yttrium-90 Radioembolization Segmentectomy for Hepatocellular Carcinoma

    by Mohammad Elsayed, William Wagstaff, Keywan Behbahani, Alexander Villalobos, Zachary Bercu, Bill S. Majdalany, Mehmet Akce, David M. Schuster, Hui Mao, Nima Kokabi

    Purpose Metformin is associated with improved outcomes after external radiation and chemotherapy but has not been studied for Y-90 radiation segmentectomy (RS). This study evaluates the effect of metformin on tumor response after Y-90 RS in patients with hepatocellular carcinoma (HCC). Methods and Materials A retrospective analysis of patients with HCC who underwent Y-90 RS between 2014–2018 was performed. Comparisons were made between all patients taking and not taking metformin, and diabetic patients taking and not taking metformin. Tumor response was analyzed with logistic regression to compare absolute and percent change in total tumor diameter (TTD) and modified Response Evaluation Criteria in Solid Tumors (mRECIST). Overall survival (OS) was evaluated using Kaplan–Meier estimation and log-rank analysis. Results A total of 106 patients underwent 112 Y-90 RS, of which 40 were diabetic (38.8%) and 19 (18.4%) were on metformin. At baseline, the two groups of patients on metformin and not on metformin had no significant difference in age, Child–Pugh score, MELD score, ALBI grade, total tumor diameter, and size of dominant tumor. The only significant baseline difference was ECOG status. Uni- and multivariate analysis demonstrated a larger reduction in TTD and objective response by mRECIST criteria for patients undergoing Y-90 RS on metformin compared to those not on metformin. OS was similar between patients taking and not taking metformin (p = 0.912). Conclusion Metformin may be associated with increased tumor response after Y-90 RS in patients with HCC. Level of Evidence III, Retrospective Study.


  • Systematic Review of Radiation-Based Therapies for Hepatocellular Carcinoma

    by Namita E. Mathew, Mohammad Elsayed, Nariman Nezami, Bill S. Majdalany, Ripal Gandhi, Michael Haber, Zachary L. Bercu, Nima Kokabi

    Aim Despite the increasing trend to utilize radiation therapies for the treatment of hepatocellular carcinoma (HCC), there is limited analysis comparing treatment outcomes of various radiation-based therapies including selective internal radiation therapy (SIRT) to stereotactic body radiation therapy (SBRT) and proton beam therapy (PBT). This study aims to examine the heterogeneity of designs and outcomes in existing radiation therapy studies for the treatment of HCC. Methods A systematic review was performed to compare the radiation therapies for HCC including SBRT, PBT, and yttrium-90 (Y90) SIRT by searching through PubMed, EMBASE, Medline, and Cochrane library databases. The main outcomes analyzed were overall survival rates, median overall survival, and progression-free survival with additional analysis of baseline patient characteristics, including Barcelona Clinic Liver Cancer stage, Child–Pugh class, and tumor size. Results Eighty-seven studies comprising 7,462 patients were included. The pooled 1-year overall survival rates for the Y90 SIRT, SBRT, and PBT groups were 57.8, 83.1, and 78.7%, respectively. The rates of Barcelona Clinic Liver Cancer A, B, and C patients were 22.9, 32.2, and 42.5% in Y90 SIRT; 52.5, 20.2, and 25.1% in SBRT; and 36.3, 33.4, and 28.2% in PBT groups, respectively. The baseline intergroup differences were statistically significant (p < 0.0001). The median tumor sizes were 5.8, 3.1, and 4.5 cm in the Y90 SIRT, SBRT, and PBT groups, respectively. Conclusion In the management of HCC, there is substantial heterogeneity in studies investigating Y90 SIRT, SBRT, and PBT, with Y90 SIRT patients having worse Barcelona Clinic Liver Cancer and tumor burden at baseline, which likely contributes to the observed lower survival outcome.